These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27471681)

  • 1. Cancer as an immune-mediated disease.
    Shurin MR
    Immunotargets Ther; 2012; 1():1-6. PubMed ID: 27471681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dendritic cell tool for oral cancer treatment.
    Anne Gowda VM; Smitha T
    J Oral Maxillofac Pathol; 2019; 23(3):326-329. PubMed ID: 31942108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment duration with immune-based therapies in Cancer: an enigma.
    Bantia S; Choradia N
    J Immunother Cancer; 2018 Dec; 6(1):143. PubMed ID: 30518409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate.
    Meirow Y; Kanterman J; Baniyash M
    Front Immunol; 2015; 6():523. PubMed ID: 26528286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Tumor Immunology and Immunotherapy in Mice.
    Buqué A; Galluzzi L
    Trends Cancer; 2018 Sep; 4(9):599-601. PubMed ID: 30149876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
    Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
    Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the tumor microenvironment of Ewing sarcoma.
    Morales E; Olson M; Iglesias F; Luetkens T; Atanackovic D
    Immunotherapy; 2021 Dec; 13(17):1439-1451. PubMed ID: 34670399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.
    Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
    Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
    J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fundamentals of immunology for understanding immunotherapy for lymphoma.
    Ansell SM
    Blood Adv; 2020 Nov; 4(22):5863-5867. PubMed ID: 33232478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance.
    Traba J; Sack MN; Waldmann TA; Anton OM
    Front Immunol; 2021; 12():657293. PubMed ID: 34079545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
    Finn OJ
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.
    Sheen MR; Fiering S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1524. PubMed ID: 29667346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.